Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
58
CANC Quote, Financials, Valuation and Earnings
Last price:
$35.48
Seasonality move
:
2.12%
Day range:
$35.35 - $35.83
52-week range:
$20.10 - $36.14
Dividend yield:
0.06%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
9.7K
Avg. volume:
30.5K
1-year change:
42.37%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- |
|
HRTS
Tema Heart & Health ETF
|
-- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
$35.41 | -- | -- | -- | $0.02 | 0.06% | -- |
|
BMED
iShares Health Innovation Active ETF
|
$30.71 | -- | -- | -- | $0.01 | 0% | -- |
|
HRTS
Tema Heart & Health ETF
|
$35.66 | -- | -- | -- | $0.47 | 1.33% | -- |
|
IBB
iShares Biotechnology ETF
|
$172.03 | -- | -- | -- | $0.18 | 0.23% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$26.78 | -- | -- | -- | $0.16 | 1.15% | -- |
|
IXJ
iShares Global Healthcare ETF
|
$98.19 | -- | -- | -- | $0.60 | 1.39% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | 0.905 | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | 0.918 | -- | -- |
|
HRTS
Tema Heart & Health ETF
|
-- | 0.753 | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | 0.865 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 0.936 | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | 0.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CANC
Tema Oncology ETF
|
-- | -- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- | -- |
|
HRTS
Tema Heart & Health ETF
|
-- | -- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
Tema Oncology ETF vs. Competitors
-
Which has Higher Returns CANC or BMED?
iShares Health Innovation Active ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat iShares Health Innovation Active ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- BMEDiShares Health Innovation Active ETF-- -- -- -
What do Analysts Say About CANC or BMED?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Health Innovation Active ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than iShares Health Innovation Active ETF, analysts believe Tema Oncology ETF is more attractive than iShares Health Innovation Active ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 BMEDiShares Health Innovation Active ETF0 0 0 -
Is CANC or BMED More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Health Innovation Active ETF has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.904%.
-
Which is a Better Dividend Stock CANC or BMED?
Tema Oncology ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.06%. iShares Health Innovation Active ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Tema Oncology ETF pays -- of its earnings as a dividend. iShares Health Innovation Active ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or BMED?
Tema Oncology ETF quarterly revenues are --, which are smaller than iShares Health Innovation Active ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than iShares Health Innovation Active ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while iShares Health Innovation Active ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for iShares Health Innovation Active ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- BMEDiShares Health Innovation Active ETF-- -- -- --
-
Which has Higher Returns CANC or HRTS?
Tema Heart & Health ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat Tema Heart & Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- HRTSTema Heart & Health ETF-- -- -- -
What do Analysts Say About CANC or HRTS?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Heart & Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than Tema Heart & Health ETF, analysts believe Tema Oncology ETF is more attractive than Tema Heart & Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 HRTSTema Heart & Health ETF0 0 0 -
Is CANC or HRTS More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Heart & Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANC or HRTS?
Tema Oncology ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.06%. Tema Heart & Health ETF offers a yield of 1.33% to investors and pays a quarterly dividend of $0.47 per share. Tema Oncology ETF pays -- of its earnings as a dividend. Tema Heart & Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or HRTS?
Tema Oncology ETF quarterly revenues are --, which are smaller than Tema Heart & Health ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than Tema Heart & Health ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while Tema Heart & Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for Tema Heart & Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- HRTSTema Heart & Health ETF-- -- -- --
-
Which has Higher Returns CANC or IBB?
iShares Biotechnology ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- IBBiShares Biotechnology ETF-- -- -- -
What do Analysts Say About CANC or IBB?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than iShares Biotechnology ETF, analysts believe Tema Oncology ETF is more attractive than iShares Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 IBBiShares Biotechnology ETF0 0 0 -
Is CANC or IBB More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.759%.
-
Which is a Better Dividend Stock CANC or IBB?
Tema Oncology ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.06%. iShares Biotechnology ETF offers a yield of 0.23% to investors and pays a quarterly dividend of $0.18 per share. Tema Oncology ETF pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or IBB?
Tema Oncology ETF quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- IBBiShares Biotechnology ETF-- -- -- --
-
Which has Higher Returns CANC or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About CANC or IDNA?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe Tema Oncology ETF is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is CANC or IDNA More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.579%.
-
Which is a Better Dividend Stock CANC or IDNA?
Tema Oncology ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.06%. iShares Genomics Immunology and Healthcare ETF offers a yield of 1.15% to investors and pays a quarterly dividend of $0.16 per share. Tema Oncology ETF pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or IDNA?
Tema Oncology ETF quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
-
Which has Higher Returns CANC or IXJ?
iShares Global Healthcare ETF has a net margin of -- compared to Tema Oncology ETF's net margin of --. Tema Oncology ETF's return on equity of -- beat iShares Global Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANCTema Oncology ETF-- -- -- IXJiShares Global Healthcare ETF-- -- -- -
What do Analysts Say About CANC or IXJ?
Tema Oncology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Global Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Tema Oncology ETF has higher upside potential than iShares Global Healthcare ETF, analysts believe Tema Oncology ETF is more attractive than iShares Global Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings CANCTema Oncology ETF0 0 0 IXJiShares Global Healthcare ETF0 0 0 -
Is CANC or IXJ More Risky?
Tema Oncology ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Global Healthcare ETF has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.078%.
-
Which is a Better Dividend Stock CANC or IXJ?
Tema Oncology ETF has a quarterly dividend of $0.02 per share corresponding to a yield of 0.06%. iShares Global Healthcare ETF offers a yield of 1.39% to investors and pays a quarterly dividend of $0.60 per share. Tema Oncology ETF pays -- of its earnings as a dividend. iShares Global Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANC or IXJ?
Tema Oncology ETF quarterly revenues are --, which are smaller than iShares Global Healthcare ETF quarterly revenues of --. Tema Oncology ETF's net income of -- is lower than iShares Global Healthcare ETF's net income of --. Notably, Tema Oncology ETF's price-to-earnings ratio is -- while iShares Global Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tema Oncology ETF is -- versus -- for iShares Global Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANCTema Oncology ETF-- -- -- -- IXJiShares Global Healthcare ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
